利奈唑胺片剂有效治疗气道支架相关肺部MRSA感染

Linezolid( Rina Thiazole Amine) Tablet is Effective in Treatment of Airway Stent Associated Infection with MRSA

目的评价利奈唑胺治疗气道支架相关肺部MRSA感染的疗效和安全性。方法14例确诊的气道支架相关肺部MRSA感染患者,接受利奈唑胺治疗10～14天。观察和记录治疗前后体温、血常规、肝肾功能和其他临床症状的改变,评价治疗的有效性和安全性。根据支气管镜下保护性毛刷刷检细菌学培养结果,评价治疗后细菌清除情况。结果本组14例患者,治疗有效率为100%。应用利奈唑胺后MRSA的清除率71.43%。治疗后患者症状明显改善：体温从38.18±0.18℃降至36.44±0.07℃（P=0.000）。气促评分从1.00±0.16降至0.50±0.13（P=0.046）。白细胞计数和CRP明显改善。白细胞计数从（10.83±0.21）×10^9/L降至（7.55±0.41）×10^9/L（P=0.003）;CRP从23.48±6.13mg/L降至5.07±1.29mg/L（P=0.001）。有1例出现腹泻,1例出现恶心不适,未观察到其他不良反应。结论利奈唑胺片剂治疗气道支架相关肺部MRSA感染,用药方便,疗效明显,不良反应少,可作为此类疾病的首选药物之一。

Objective To evaluate the effects of linezolid （rina thiazole amine） in the treatment of airway stent associated infection with MRSA. Methods Patients with airway stent associated infection of MRSA （n=14） were treated with Linezolid （rina thiazole amine） for 10-14 days. The body temperature, blood routine test, liver and kidney function and other clinical symptoms and indicators were compared before and after treatment, in order to evaluate the efficacy and safety of treatment. The eliminating rate for MRSA bacteria was evaluated by bronchoscopic protective hair brush bacteriology. Results The study included 14 patients. All patients responded to Linezolid treatment and the effective rate was 100%. The MRSA clearance rate was 71.43% after Linezolid treatment. The infection related symptoms were significantly improved after treatment. The body temperature decreased from 38.18±0.18℃ to 36.44±0.07℃ （P=0.000）. Apnea score decreased from 1.00±0.16 to 0.50±0.13（P=0.046）. Leukocyte count decreased from （10.83±0.21）×10^9/L to （7.55±0.41）×10^9/L（P=0.003）; CRP decreased from 23.48±6.13 mg/L to 5.07±1.29 mg/L （P=0.001）. Diarrhea occurred in one patient, and nausea occurred in another patient. No other side effects were observed. Conclusion Linezolid tablets is effective and safe in treatment of stents associated airway infection with MRSA, which provides a therapeutic strategy for airway stent associated infection.